DelveInsight’s, “Mantle Cell Lymphoma Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including Mantle Cell Lymphoma clinical trials and nonclinical stage products. It also covers the Mantle Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Mantle Cell Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mantle Cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Mantle Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Mantle Cell Lymphoma Pipeline Report
- DelveInsight’s Mantle Cell Lymphoma pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Mantle Cell Lymphoma treatment.
- The leading Mantle Cell Lymphoma Companies includes Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical, Eli Lilly and Company, and others.
- Promising Mantle Cell Lymphoma Pipeline Therapies includes Ibrutinib, Venetoclax, Bendamustine, Rituximab, Ibrutinib, Acalabrutinib in combination with BR, Gemcitabine, Mitoxantrone, DTRMWXHS-12, and others.
- The Mantle Cell Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence R&D Mantle Cell Lymphoma. The Mantle Cell Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve Mantle Cell Lymphoma.
To explore more information on the latest breakthroughs in the Mantle Cell Lymphoma Pipeline treatment landscape of the report, click here @ Mantle Cell Lymphoma Pipeline Outlook
Mantle Cell Lymphoma Overview
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) usually identified by a translocation of the CCND1 gene. The variety of morphologic variants may make this a challenging diagnosis, although most cases are uncomplicated. It typically follows an aggressive clinical course, although an indolent leukemia variant has been described. MCL is characterized by reciprocal chromosomal translocation t(11;14)(q13:q32), resulting in juxtapositioning of cyclin D1 locus to immunoglobulin heavy chain gene locus. This leads to constitutive expression of cyclin D1 (CCND1), which plays a significant role in tumor cell proliferation via cell cycle dysregulation, chromosomal instability, and epigenetic regulation. Rare cases without this translocation may have a CCND2 or 3 translocations. Hypothetical models of molecular subtypes have been proposed based on the cell of origin that correlates to clinical phenotypes. Arising from naive B cells that have no or limited iGVH mutations and express SOX 11 are the classical MCL or aggressive MCL. SOX 11 is a neural transcription factor reported to block terminal B cell differentiation. Arising from antigen-experienced B cells that have undergone IGVH somatic hypermutations and typically SOX 11 negative and genetically stable B cells are the indolent variant of MCL
Mantle Cell Lymphoma Emerging Drugs Profile
Venetoclax: AbbVie
Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis. Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S. Currently the product is in Phase III for mantle cell lymphoma.
Daratumumab: Janssen Pharmaceutical
Daratumumab is a first-in-class3 biologic targeting CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage.4 Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well as through apoptosis, in which a series of molecular steps in a cell lead to its death. Currently the product is in Phase II for the treatment of Mantle Cell Lymphoma.
For further information, refer to the detailed Mantle Cell Lymphoma Unmet Needs, Mantle Cell Lymphoma Market Drivers, and Market Barriers, click here for Mantle Cell Lymphoma Ongoing Clinical Trial Analysis
Mantle Cell Lymphoma Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies Mantle Cell Lymphoma. The companies which have their Mantle Cell Lymphoma drug candidates in the most advanced stage, i.e phase III include Abbvie
Mantle Cell Lymphoma Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request a sample and discover the recent advances in Mantle Cell Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Mantle Cell Lymphoma Treatment Landscape
Scope of the Mantle Cell Lymphoma Pipeline Insight Report
- Coverage- Global
- Mantle Cell Lymphoma Companies- Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical, Eli Lilly and Company, and others.
- Mantle Cell Lymphoma Pipeline Therapies- Ibrutinib, Venetoclax, Bendamustine, Rituximab, Ibrutinib, Acalabrutinib in combination with BR, Gemcitabine, Mitoxantrone, DTRMWXHS-12, and others.
- Mantle Cell Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Mantle Cell Lymphoma Market Drivers and Mantle Cell Lymphoma Market Barriers, click here @ Mantle Cell Lymphoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Mantle Cell Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Mantle Cell Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Venetoclax: AbbVie
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Daratumumab: Janssen Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BGB 16673: BeiGene
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Mantle Cell Lymphoma Key Companies
- Mantle Cell Lymphoma Key Products
- Mantle Cell Lymphoma- Unmet Needs
- Mantle Cell Lymphoma- Market Drivers and Barriers
- Mantle Cell Lymphoma- Future Perspectives and Conclusion
- Mantle Cell Lymphoma Analyst Views
- Mantle Cell Lymphoma Key Companies
- Appendix
Got Queries? Find out the related information on Mantle Cell Lymphoma Mergers and acquisitions, Mantle Cell Lymphoma licensing activities @ Mantle Cell Lymphoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
